Latest News and Press Releases

CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

Multifaceted activity of brilaroxazine supports potential for improvement in behavioral symptoms as well as accompanying neuroinflammation This proof-of-concept data supported the initial clinical...

CUPERTINO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical...

CUPERTINO, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies...

- Topline data for pivotal Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia expected in mid-2023 - Brilaroxazine is a serotonin/dopamine modulator with a differentiated...

- RP1208 is in preclinical development for the potential treatment of depression and obesity – - Composition of matter patents for RP1208 have been granted in key markets around the world including...